CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
Epidiolex 100 mg/mL Oral Solution +1 moredrug
Likely dose
Epidiolex 100 mg/mL Oral Solutionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04642404
NCT04642404Phase 2Completed
CompareCT.gov

Cannabidiol (CBD) for the Management of Emergency Dental Pain

The University of Texas Health Science Center at San Antonio·interventional·Posted Nov 24, 2020·Updated May 9, 2024

In Brief

A Phase 2 clinical trial evaluating Epidiolex 100 mg/mL Oral Solution and Placebo for Odontalgia and Toothache. Completed, enrolled 64 participants across 1 site.

Detailed Summary

The purpose of this study is to evaulate CBD as a therapeutic approach for dental pain. Eligible subjects presented with emergency dental pain will be give a single dose of Epidiolex (FDA-approved CBD) or placebo and will be monitored for 3 hours for pain symptoms and psychologic effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOdontalgia, Toothache
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedNov 24, 2020
Enrollment StartMar 1, 2021
Primary CompletionMar 2, 2023
Study CompletionMar 13, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.6 years ago

Interventions

Epidiolex 100 mg/mL Oral Solutiondrug

Cannabidiol (CBD): is the primary non-psychoactive and non-addictive compound in cannabis, has already shown potential in treating pain such as arthritis, neuropathic, cancer and chronic pain

Placebodrug

Placebo drug will be a solution with the same taste, texture and color as the drug.